Active substance
Recombinant respiratory syncytial virus prefusion f protein adjuvanted with as01e
- SFDA 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Arexvy | 120 µg | Powder and suspension for suspension for injection · Intramuscular use | 1 Vial | SAR 925.65 | Biological · Prescription | Glaxo Saudi Arabia Ltd. | Valid |
Indications — CHI Daman Drug Formulary
ADULT IMMUNIZATION; CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)-PREVENTION OF EXACERBATIONS; RESPIRATORY SYNCYTIAL VIRUS - VACCINATION
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.